Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma.

Although there were trends towards a greater percentage increase in FEV 1 (127% and 129% increase at 4–6 months and 1 year for benralizumab, respectively, vs 108% and 109% for mepolizumab and 106% and 103% for benralizumab, respectively) and PEFR (125% and 125% increase at 4–6 months and 1 year for benralizumab, respectively, vs 109% and 105% for mepolizumab and 109% and 117% for benralizumab, respectively) from baseline in patients taking benralizumab ( Figure 3 ), these differences did not reach statistical significance (p > 0.05).

also in 111,027 other papers